The Pituitary-Thyroid Axis and Prolactin Secretion in Hemodialysis Patients in Two Endemic Regions of Eastern GermanyMorphologic and laboratory abnormalities of the thyroid gland in CKD5D patients
received 27. Juni 2017
first decision 19. Oktober 2017
accepted 15. November 2017
23. Februar 2018 (online)
Introduction Endocrine disorders of the pituitary axes are frequent in patients with hemodialysis (CKD5D). The aim of this multicenter study (Leipzig (L), Quedlinburg and Blankenburg in the Harz region (Hz)) in CKD5D patients was to evaluate influences of CKD5D related factors, morphological and biochemical parameters, and serum iodine and prolactin concentrations on the pituitary-thyroid axis.
Patients and Methods 170 patients (L n=58; Hz n=112) were included in this prospective, non-interventional, cross-sectional study. Mann-Whitney-U-test and bivariate correlation analyses with Spearman-Rho test (r correlation coefficient) were used in statistical analysis.
Results TSH was higher in patients with prolactin concentrations>370 mIU/l (p=0.013), in patients with high flux membranes (p=0.0013) and in patients with longer dialysis vintage (p=0.04). Median iodine serum concentrations were slightly elevated in the Leipzig cohort (p=0.001) and correlated with fT4 (p<0.001, r=0.43) and albumin (p=0.001, r=0.245) but not with morphological signs. Albumin was correlated with fT3 (p<0.001, r=0.339) and fT4 (p<0.001, r=0.421). Prolactin was correlated with residual excretion rate (p=0.001, r=- 0.303) and thyroid volume (p=0.027, r=0.217).
Conclusions In the assessment of the thyroid status in CKD5D patients, the synopsis of the clinical and nutritional status, comorbidities, ultrasound of the thyroid gland and laboratory results is necessary for further intervention with hormone replacement. Standardized reference values of the pituitary-thyroid axis should be critically evaluated and are still lacking in CKD5D.
Key wordspituitary-thyroid axis - TSH - fT3 - fT4 - iodine serum concentration - prolactin - hemodialysis - goiter - nodule
* Both authors contributed equally
- 1 Meuwese CL, Carrero JJ. Chronic kidney disease and hypothalamic-pituitary axis dysfunction: The chicken or the egg?. Arch Med Res 2013; 44: 591-600
- 2 Lebkowska U, Malyszko J, Mysliwiec M. Thyroid function and morphology in kidney transplant recipients, hemodialyzed, and peritoneally dialyzed patients. Transplant Proc. 2003; 35: 2945-2948
- 3 Pahlka RB, Sonnad JR. The effects of dialysis on 131I kinetics and dosimetry in thyroid cancer patients–a pharmacokinetic model. Health Phys. 2006; 91: 227-237
- 4 Gómez de Oña C, Martínez-Morillo E, Gago González E. et al. Variation of trace element concentrations in patients undergoing hemodialysis in the north of Spain. Scand J Clin Lab Invest. 2016; 76: 492-499
- 5 Tonelli M, Wiebe N, Hemmelgarn B. et al. Trace elements in hemodialysis patients: A systematic review and meta-analysis. BMC Med 2009; 7: 25
- 6 Hegedüs L, Andersen JR, Poulsen LR. et al. Thyroid gland volume and serum concentrations of thyroid hormones in chronic renal failure. Nephron 1985; 40: 171-174
- 7 Sanai T, Okamura K, Inoue T. et al. Ultrasonographic detection of thyroid nodules in hemodialysis patients in Japan. Ther Apher Dial. 2010; 14: 323-327
- 8 Jusufovic S, Hodzic E. Functional thyroid disorders are more common in patients on chronic hemodialysis compared with the general population. Mater Sociomed 2011; 23: 206-209
- 9 Sanai T, Okamura K, Kishi T. et al. Importance of specific reference values for evaluation of the deteriorating thyroid function in patients with end-stage renal disease on hemodialysis. J Endocrinol Invest. 2015; 38: 47-56
- 10 de Pablo-Davila F, Miralles-Garcia JM, Hernandez-Miguel E. et al. Study of the kinetics of the thyroid hormones and the peripheral conversion rate of thyroxine to triiodothyronine in acute renal insufficiency under experimental conditions. Horm Metab Res. 1980; 12: 529-536
- 11 Gómez F, de La Cueva R, Wauters JP. et al. Endocrine abnormalities in patients undergoing long-term hemodialysis. The role of prolactin. Am J Med. 1980; 68: 522-530
- 12 Sharma LK, Sharma N, Gadpayle AK. et al. Prevalence and predictors of hyperprolactinemia in subclinical hypothyroidism. Eur J Intern Med. 2016; 35: 106-110
- 13 Hou SH, Grossman S, Molitch ME. Hyperprolactinemia in patients with renal insufficiency and chronic renal failure requiring hemodialysis or chronic ambulatory peritoneal dialysis. Am J Kidney Dis. 1985; 6: 245-249
- 14 Yavuz D, Topçu G, Ozener C. et al. Macroprolactin does not contribute to elevated levels of prolactin in patients on renal replacement therapy. Clin Endocrinol (Oxf) 2005; 63: 520-524
- 15 Sayki Arslan M, Sahin M, Topaloglu O. et al. Hyperprolactinaemia associated with increased thyroid volume and autoimmune thyroiditis in patients with prolactinoma. Clin Endocrinol (Oxf) 2013; 79: 882-886
- 16 Foulks CJ, Cushner HM. Sexual dysfunction in the male dialysis patient: Pathogenesis, evaluation, and therapy. Am J Kidney Dis. 1986; 8: 211-222
- 17 Letizia C, Mazzaferro S, de Ciocchis A. et al. Effects of haemodialysis session on plasma beta-endorphin, ACTH and cortisol in patients with end-stage renal disease. Scand J Urol Nephrol. 1996; 30: 399-402
- 18 Grussendorf M, Reiners C, Paschke R. et al. Reduction of thyroid nodule volume by levothyroxine and iodine alone and in combination: A randomized, placebo-controlled trial. J Clin Endocrinol Metab. 2011; 96: 2786-2795
- 19 Emmanouel DS, Fang VS, Katz AI. Prolactin metabolism in the rat: Role of the kidney in degradation of the hormone. Am J Physiol. 1981; 240: F437-F445
- 20 Thienpont LM, van Uytfanghe K, van Houcke S. et al. A Progress Report of the IFCC Committee for Standardization of Thyroid Function Tests. Eur Thyroid J. 2014; 3: 109-116
- 21 Yonemura K, Nakajima T, Suzuki T. et al. Low free thyroxine concentrations and deficient nocturnal surge of thyroid-stimulating hormone in haemodialysed patients compared with undialysed patients. Nephrol Dial Transplant. 2000; 15: 668-672
- 22 Lo JC, Beck GJ, Kaysen GA. et al. Thyroid function in end stage renal disease and effects of frequent hemodialysis. Hemodial Int 2017; DOI: 10.1111/hdi.12527.
- 23 Meuwese CL, Dekker FW, Lindholm B. et al. Baseline levels and trimestral variation of triiodothyronine and thyroxine and their association with mortality in maintenance hemodialysis patients. Clin J Am Soc Nephrol. 2012; 7: 131-138
- 24 Rhee CM, You AS, Nguyen DV. et al. Thyroid status and mortality in a prospective hemodialysis cohort. J Clin Endocrinol Metab. 2017; 102: 1568-1577
- 25 Sharma N, Dutta D, Sharma L. Occurrence of hyperprolactinemia in children with subclinical hypothyroidism. J Clin Res Pediatr Endocrinol 2017; DOI: 10.4274/jcrpe.4536.
- 26 Veighey K, Booth J, Davenport A. Does the choice of phosphate binder affect trace element levels in chronic kidney disease patients treated by regular haemodialysis?. Nephrol Dial Transplant 2011; 26: 1006-1010
- 27 Zimmermann MB, Andersson M. Assessment of iodine nutrition in populations: past, present, and future. Nutr Rev. 2012; 70: 553-570
- 28 Bath SC, Pop VJM, Furmidge-Owen VL. et al. Thyroglobulin as a functional biomarker of iodine status in a cohort study of pregnant women in the United Kingdom. Thyroid 2017; 27: 426-433
- 29 Ma ZF, Skeaff SA. Thyroglobulin as a biomarker of iodine deficiency: A review. Thyroid 2014; 24: 1195-1209